Cautious Optimism for Biosimilars in Rheumatology

Save

CHMP Recommend Baricitinib for Approval in Europe

Save

Eli Lilly and Company announced last friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib for the treatment of adults with moderate to severely active rheumatoid arthritis (R

Risk of GI Perforations on Biologics

Save

Gastrointestinal perforation is a rare but serious complication that RA patients may be at particular risk for.

RheumNow Week in Review – 16 December 2016

Save

Dr. Jack Cush reviews highlights from this week on RheumNow.com

EULAR 2016 Recommendations on Early Arthritis

Save

Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.

Supreme Court Declines Biosimilar Patent Dispute

Save

The U.S. Supreme Court has declined to hear a case over whether companies that make biosimilar drugs must wait six months after federal approval before they bring them to the market.

Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes

Save

Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients. 

Rituximab May Reduce Mortality Risk in Rheumatoid Lung Disease

Save

While it is known that rheumatoid arthritis (RA) patients with interstitial lung involvement is associated with severe seropositive disease and is associated with an increased mortality.

Herpes Zoster and GCA – What’s the Deal?

Save

In November I reported on an abstract presented at ACR by Muratore, et al. who looked for evidence of VZV infection in temporal artery biopsies of GCA patients and found none.

Nonsignificant CV Risk with Actemra vs Enbrel

Save

WASHINGTON -- Rheumatoid arthritis is a recognized risk factor for heart attacks and stroke, but a study comparing two leading biologics found only a non-significant increase in relative risk for patients treated with toclizimab (Actemra) vs etanercept (Enbrel), researchers reported here.

Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study

Save

The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.

Is ABT-494 the Next JAK Inhibitor?

Save

Tofacitinib may well be joined by a new once daily JAK inhibitor, baricitinib in the next few months.

The RheumNow Week in Review – 2 December 2016

Save

Dr. Cush highlights reports from this week on RheumNow.com.

Ustekinumab Effective and Safe in Crohn's Colitis

Save

The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)

ACR16 Day 4 Ends with Rheumatology Roundup

Save

The final day of the 2016 annual ACR meeting saw the return of "Rheumatology Round-up" at 7:30am in Hall D.

Dual Cytokine Inhibition for RA

Save

The notion of a single biologic targeting two cytokines is intriguing. ABT-122 is a new dual-variable domain immunoglobulin that neutralizes both TNF-α and IL-17A.

Tocilizumab Infections Less in ACPA+ Patients

Save

Tocilizumab is in the spotlight at this year’s ACR 2016 meeting but there is still much to learn, including more about its safety profile. In an abstract presented at today’s poster session (Abstract 2618), Morel, et al.

CORRONA Presentations at ACR 2016

Save

CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.

Two New Biologics for Polyarticular JIA

Save

On Monday, November 13, there were two new presentations at the annual ACR 2016 meeting on new biologics seeking approval for use in polyarticular juvenile arthritis.

RheumNow Week in Review – 11 November 2016

Save

Dr Cush reviews highlights from this week on RheumNow.com